Newswise — Baltimore, April 12, 2022— Two new studies from the Global Virus Network, including the University of Maryland’s Institute of Human Virology and in partnership with the Petroleum Industry Health Organization of Iran, provide evidence that getting the oral polio vaccine made from live, weakened polio-virus may protect people from COVID-19 infection by stimulating the immune system. 

One of these studies demonstrated a lower incidence of COVID infections in countries in which people received the ‘live’ polio vaccine compared to countries that only received the polio vaccine that does not contain a live virus. These findings were published on March 17, 2022, in PLOS One.

Another report from the research team showed that when young children received the ‘live’ polio vaccine their mothers, who were indirectly exposed to the poliovirus vaccine, did not get infected with COVID. This study was published late last year in JAMA Network Open.

Within a few hours of exposure to any pathogens — including weakened viruses like those in the oral polio vaccine — the immune system activates its first line-of-defense. This defense produces an immune response to a broad variety of pathogen-related molecules and ramps up the immune system’s readiness for invaders — a process sometimes called ‘trained innate immunity.’ The outcome from one of these newest studies indicate that this trained innate immune response spurred by vaccination using the live polio-virus may provide protection for up to 6 months against COVID infection. 

The researchers say that this implies that these live vaccines, technically known as live attenuated vaccines, may be used temporarily to protect people in low-income countries that do not yet have access to COVID vaccines.

“Although countries like the U.S. and those in Europe are dropping pandemic restrictions, many people in lower income countries remain unvaccinated due to lack of supply. Individuals in these countries are still at high risk for COVID infection and potential complications, particularly since these regions still lack the latest treatments and enough ventilators for those who need them,” said co-author Shyam Kottilil, MBBS, PhD, Professor of Medicine and Director of the Division of Clinical Care and Research, Institute of Human Virology, Chief of the Division of Infectious Diseases at the University of Maryland School of Medicine, and senior advisor to the GVN. “These live vaccines may provide a stop gap to reduce hospitalizations and deaths until we can get these people COVID vaccines.”

Senior author on the studies, Robert Gallo, MD, The Homer & Martha Gudelsky Distinguished Professor in Medicine, Co-Founder and Director of the Institute of Human Virology at the University of Maryland School of Medicine, a GVN Center of Excellence, and Co-Founder of the GVN and Chair of the GVN’s Scientific Leadership Board, said, “Early in the COVID-19 pandemic, prior to development of effective vaccines we proposed using live attenuated vaccines as a temporary solution to boost immunity until the vaccine could be developed. This idea directly stemmed from my GVN colleague and co-author Dr. Konstantin Chumakov, whose parents were vaccine researchers in the 1970s Soviet Union. His parents observed that flu rates seemed to drop in those people given the oral polio vaccine. Other GVN colleagues joined us in advocating for studies to determine if these live attenuated vaccines would be a feasible strategy during the coronavirus pandemic. Now we have some of the first evidence that they do offer protection. I hope funders take notice and increase support for these types of trials that study the innate immune response and provide significant hope in mitigating future pandemics.” 

Christian Bréchot, MD, PhD, President of the GVN, Associate Vice President for International Partnerships and Innovation at University of South Florida (USF), and Professor, Division of Infectious Disease, Department of Internal Medicine at the USF Health Morsani College of Medicine, the GVN Southeast U.S. Regional Headquarters said, “The GVN serves as a catalyst to bring together the world’s foremost virologists. We are pleased to work with varying nations to initiate these important clinical trials.”

Co-author Konstantin Chumakov, PhD, a GVN Center of Excellence Director said, "These observations are yet another confirmation that live vaccines induce broad protection against infections caused by pathogens other than their direct target. They urgently call for the direct prospective clinical studies of this phenomenon that could lead to the development of a novel class of vaccines based on stimulation of trained innate immunity. Such vaccines could become the badly needed universal countermeasure against emerging infections.” 

In the PLOS One study, the researchers compared infection rates per 100,000 people in 146 countries that received both the live and the injectable polio vaccine, which does not contain live virus, compared to 56 countries that only used the injectable, non-live version. They found infection rates in countries that did not use the live polio vaccine were about three times higher than those that did use the live polio vaccine. 

For the JAMA Network Open study, the researchers followed 419 mothers in Iran whose young children were given the live polio vaccine compared to 3,771 mothers whose children did not receive the live polio vaccine. None of the mothers whose children received the live polio vaccine developed COVID, whereas 28 mothers whose children did not receive the live polio vaccine did contract COVID within 9 months. Researchers know that polio-virus and even the weakened virus from the vaccine can be shed in the stool. The researchers surmise that the mothers were exposed to virus when caring for their children through bathing and diaper changing.

“It is heartening to find similar study results obtained from very different approaches strengthening our hypothesis that using the oral vaccine may provide protection against SARS-CoV-2, the virus that causes COVID,” said the first author on the studies, Farrokh Habibzadeh, MD, Special Consultant on Public Health for the GVN and the Managing Director of the Research & Development Unit of the Petroleum Industry Health Organization of Shiraz, Iran. He added that, “This hypothesis should be tested in additional quality clinical trials, preferably conducted in countries where the oral polio vaccine is currently in use as part of their national immunization for polio.”

Co-author Kristen Stafford, PhD, MPH, Associate Professor of Epidemiology & Public Health at the Institute of Human Virology at the University of Maryland School of Medicine and member of the GVN, said, “Some high-income countries declare pandemics over when in fact they just transition to only affecting low-income countries. We do not want this pandemic to become like the HIV-epidemic, where years and years of delays led to millions of excess deaths because the antiretroviral medications were too limited in supply or expensive to reach those disproportionately affected. We need to find simpler, inexpensive solutions to protect people until they can get their full doses and boosters of the COVID vaccines.”

“The important observations that the oral polio vaccine may protect against different infections such as COVID-19 is crucial for future pandemic preparedness. Understanding the mechanisms of protection induced by the oral polio vaccine and other live attenuated vaccines can open the door for the development of improved vaccination strategies to protect against broader infections, and thus provide partial protection against new pathogens during a pandemic until specific vaccines can be developed” said Mihai Netea, MD, PhD, of the Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, a GVN Center of Excellence, and GVN Center Director.  

One of the limitations of the live, weakened vaccines, is that they are not recommended for people with suppressed immune systems, as it could lead to infection.

Additional authors on the studies include Mohammad Sajadi, MD, Professor of Medicine at the Institute of Human Virology at the University of Maryland School of Medicine and member of the GVN; and Mahboobeh Yadollahie, MD, Ashraf Simi, BScN, Saeid Saeidimehr, MD, (JAMA Network Open only), Mohammad Rafiei, MD, (JAMA Network Open only), and Iman Hafizi-Rastani, MSc (PLOS One only) of the Petroleum Industry Health Organization of Iran.

The authors received no specific funding for this work.

Dr. Kottilil received grants from Gilead for other research and serves on the advisory boards of Merck and Regeneron. 

 

About the Institute of Human Virology

Formed in 1996 as a partnership between the State of Maryland, the City of Baltimore, the University System of Maryland, and the University of Maryland Medical System, the IHV is an institute of the University of Maryland School of Medicine and is home to some of the most globally-recognized and world-renowned experts in all of virology. The IHV combines the disciplines of basic research, epidemiology, and clinical research in a concerted effort to speed the discovery of diagnostics and therapeutics for a wide variety of chronic and deadly viral and immune disorders, most notably HIV, the virus that causes AIDS. For more information, visit ihv.org and follow us on Twitter @IHVmaryland.

 

About the University of Maryland School of Medicine

Now in its third century, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States. It continues today as one of the fastest growing, top-tier biomedical research enterprises in the world -- with 46 academic departments, centers, institutes, and programs, and a faculty of more than 3,000 physicians, scientists, and allied health professionals, including members of the National Academy of Medicine and the National Academy of Sciences, and a distinguished two-time winner of the Albert E. Lasker Award in Medical Research. With an operating budget of more than $1.3 billion, the School of Medicine works closely in partnership with the University of Maryland Medical Center and Medical System to provide research-intensive, academic and clinically based care for nearly 2 million patients each year. The School of Medicine has nearly $600 million in extramural funding, with most of its academic departments highly ranked among all medical schools in the nation in research funding. As one of the seven professional schools that make up the University of Maryland, Baltimore campus, the School of Medicine has a total population of nearly 9,000 faculty and staff, including 2,500 students, trainees, residents, and fellows. The combined School of Medicine and Medical System (“University of Maryland Medicine”) has an annual budget of over $6 billion and an economic impact of nearly $20 billion on the state and local community. The School of Medicine, which ranks as the 8th highest among public medical schools in research productivity (according to the Association of American Medical Colleges profile) is an innovator in translational medicine, with 606 active patents and 52 start-up companies. In the latest U.S. News & World Report ranking of the Best Medical Schools, published in 2021, the UM School of Medicine is ranked #9 among the 92 public medical schools in the U.S., and in the top 15 percent (#27) of all 192 public and private U.S. medical schools. The School of Medicine works locally, nationally, and globally, with research and treatment facilities in 36 countries around the world. Visit medschool.umaryland.edu

 

SEE ORIGINAL STUDY